Universe Pharmaceuticals INC

UPC Nasdaq SEC CIK 1809616
Follow Universe Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · US GAAP
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$20B$0$20B$40BFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$17.9B−$3.7B
FY24$23B−$8.7B
FY23$32.3B−$6.6B
FY22$40.1M−$7.9M
FY21$48M$11.3M
FY20$30.7M$7.6M
FY19$33.2M$7.6M
FY18--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−50%−25%0%25%50%75%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2535.3%−16.3%−20.6%
FY2426.4%−34.8%−37.9%
FY2331.9%−12.3%−20.4%
FY2254.5%−17.5%−19.7%
FY2152.8%28.3%23.6%
FY2045.9%33.4%24.6%
FY1940.3%29.4%22.7%
FY18---
Free cash flowOperating cash flow minus capital expenditure
−$10B−$5B$0$5BFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$5.3B
FY24−$9.7B
FY23$1.1B
FY22−$1.4M
FY21−$2.5M
FY20$6.1M
FY19$13.1M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Universe Pharmaceuticals
  • Healthcare median
−100%−50%0%50%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearUniverse PharmaceuticalsHealthcare median
FY25−20.6%−30.6%
FY24−37.9%−47%
FY23−20.4%−58%
FY22−19.7%−80.4%
FY2123.6%−71.9%
FY2024.6%−62.2%
FY1922.7%−46.3%
FY18-−49.6%